STO · EGTX.ST
Egetis Therapeutics AB (publ)
SEK 10.34SEK 0.00 (0.0%)
Egetis Therapeutics AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 4.44% below the high.
Loading market information…
STO · SANION.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Saniona AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 59.54% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Saniona AB (publ)’s next earnings report is currently expected on Nov 26, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Saniona AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system disorders. The company's pipeline features Tesofensine, a monoamine reuptake inhibitor, and Tesomet, a fixed-dose combination of tesofensine and metoprolol, which has advanced through Phase 2 clinical trials for Prader-Willi Syndrome and hypothalamic obesity. Additionally, Saniona is progressing SAN711, currently in Phase 1 for rare neuropathic conditions, and SAN903, an early-stage candidate in preclinical development for rare inflammatory, fibrotic, and hematological ailments. Saniona also engages in various strategic collaborations, including research and partnership agreements with Boehringer Ingelheim International GmbH, a licensing deal with Productos Medix, S.A. de C.V., and both research services and collaboration agreements with Cephagenix ApS.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:37 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 10.34SEK 0.00 (0.0%)
Egetis Therapeutics AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 4.44% below the high.
SEK 70.90+SEK 0.30 (+0.42%)
Humana AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 8.87% below the high.
SEK 9.90+SEK 0.40 (+4.21%)
Vicore Pharma Holding AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 45.72% below the high.
SEK 250.00SEK 0.00 (0.0%)
Stille AB’s quoted price sits in the upper half of its reported 52-week range, 11.66% below the high.
SEK 21.80-SEK 0.20 (-0.91%)
Genovis AB’s quoted price sits in the upper half of its reported 52-week range, 7.82% below the high.
SEK 58.00-SEK 1.50 (-2.52%)
Devyser Diagnostics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 56.91% below the high.
SEK 16.76-SEK 0.72 (-4.12%)
SynAct Pharma AB’s quoted price sits in the upper half of its reported 52-week range, 31.87% below the high.
SEK 1.71+SEK 0.05 (+3.07%)
Oncopeptides AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 72.13% below the high.
